Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis

Inclusion Criteria: * Male or non-pregnant, non-lactating females 18 years of age or older. * Signed informed consent form, which meets all criteria of current FDA regulations. * If female and of child-bearing potential, have a negative urine pregnancy test at baseline visit, and prepare to abstain from sexual intercourse or use a reliable method of contraception during the study. * A total score of at least 4 for the clinical signs and symptoms of tinea pedis for the target lesion. In addition, the most infected area must have a minimum score of at least 2 for erythema and a minimum score of at least 2 for scaling. * A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. * The presence of tinea pedis infection, confirmed by the observation of segmented fungal hyphae during a microscopic 10% potassium hydroxide wet mount examination. Exclusion Criteria: * Females who are pregnant, lactating or likely to become pregnant during the study. * Use of antipruritics, including antihistamines within 72 hours prior to baseline visit. * Use of topical corticosteroids, antibiotics or antifungal therapies within 2 weeks prior to baseline visit. * Use of systemic corticosteroids, antibiotics or antifungal therapies within 1 month prior to baseline visit. * Use of oral terbinafine or itraconazole within 2 months prior to baseline visit. * Use of immunosuppressive medication…